BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32748742)

  • 1. A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma.
    Chen Z; Huang X; Lv Y; Fang Y; Pan L; Gan Z; Huang Z; Wei W
    Comb Chem High Throughput Screen; 2021; 24(2):187-194. PubMed ID: 32748742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a 4-miRNA prognostic signature for endometrial cancer.
    Huang J; Du F; Wang N
    Medicine (Baltimore); 2022 Oct; 101(41):e30974. PubMed ID: 36254064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A six-microRNA signature predicts survival of patients with uterine corpus endometrial carcinoma.
    Wang Y; Xu M; Yang Q
    Curr Probl Cancer; 2019 Apr; 43(2):167-176. PubMed ID: 29567372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a necroptosis-related prognostic model for uterine corpus endometrial carcinoma.
    Zhang Q; Luo Y; Zhang S; Huang Q; Liu G
    Sci Rep; 2024 Feb; 14(1):4257. PubMed ID: 38383747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
    Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
    Front Immunol; 2021; 12():788431. PubMed ID: 34970268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
    Zhou M; Zhang Z; Zhao H; Bao S; Sun J
    BMC Cancer; 2018 Jan; 18(1):39. PubMed ID: 29304762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma.
    Ouyang D; Li R; Li Y; Zhu X
    J Cell Biochem; 2019 Oct; 120(10):18465-18477. PubMed ID: 31168849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a Multi-RNA-Type-Based Signature for Recurrence-Free Survival Prediction in Patients with Uterine Corpus Endometrial Carcinoma.
    Wang P; Zeng Z; Shen X; Tian X; Ye Q
    DNA Cell Biol; 2020 Apr; 39(4):615-630. PubMed ID: 32105510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma.
    Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
    Cancer Med; 2018 Nov; 7(11):5632-5642. PubMed ID: 30306731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An miRNA signature associated with tumor mutation burden in endometrial cancer.
    Zhou H; Chen L; Qin M; Lei Y; Li T; Li H; Cheng X
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33141168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
    Sun XX; Wen HQ; Zhan BX; Yang P
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferroptosis-Related lncRNA for the Establishment of Novel Prognostic Signature and Therapeutic Response Prediction to Endometrial Carcinoma.
    Zhou XY; Dai HY; Zhang H; Zhu JL; Hu H
    Biomed Res Int; 2022; 2022():2056913. PubMed ID: 35937391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
    Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
    Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. m
    Fang F; Wang P; Huang H; Ye M; Liu X; Li Q
    BMC Cancer; 2022 Dec; 22(1):1364. PubMed ID: 36581816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.
    Zhou C; Li C; Yan F; Zheng Y
    Cancer Cell Int; 2020 Nov; 20(1):541. PubMed ID: 33292199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-21 expression in cancer cells is an independent biomarker of progression-free survival of endometrioid endometrial carcinoma.
    Sato K; Miyamoto M; Takano M; Tsuda H
    Virchows Arch; 2021 Nov; 479(5):883-891. PubMed ID: 34331128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of oxeiptosis-associated lncRNAs and prognosis-related signature genes to predict the immune status in uterine corpus endometrial carcinoma.
    Niu L; Wu Z
    Aging (Albany NY); 2023 May; 15(10):4236-4252. PubMed ID: 37211398
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
    Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 14-Methylation-Driven Differentially Expressed RNA as a Signature for Overall Survival Prediction in Patients with Uterine Corpus Endometrial Carcinoma.
    Zeng Z; Cheng J; Ye Q; Zhang Y; Shen X; Cai J; Li M
    DNA Cell Biol; 2020 Jun; 39(6):975-991. PubMed ID: 32397815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and prognostic value of genomic instability-derived long non-coding RNA signature of endometrial cancer.
    Huo XL; Wang SF; Yang Q; Yu XL; Gu T; Hua HX; Yang M; Bai LL; Zhang XL
    Taiwan J Obstet Gynecol; 2022 Jan; 61(1):96-101. PubMed ID: 35181055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.